Neuromuscular Blocking Agents

Neuromuscular blocking agents (NMBAs) are drugs that interrupt transmission at the neuromuscular junction to produce skeletal-muscle paralysis. In critical care they are used selectively — for example to facilitate intubation, to control severe ventilator dyssynchrony, or in early severe acute respiratory distress syndrome (ARDS) — and always alongside, never as a substitute for, adequate sedation and analgesia.

Definition

Neuromuscular blocking agents are drugs that act at the neuromuscular junction to prevent skeletal-muscle contraction, producing controlled paralysis; they are classified as depolarising or non-depolarising according to their action on the postsynaptic acetylcholine receptor.

Scope

This topic covers the pharmacological classes of neuromuscular blockers, their mechanism at the neuromuscular junction, the principal critical-care indications, and the key trial evidence in ARDS. It also notes the essential safety principle that paralysed patients require concurrent sedation and analgesia. It is a reference overview, not a guide to selecting, dosing or monitoring these agents.

Key concepts

• Neuromuscular junction and acetylcholine receptor
• Depolarising blockers (e.g. succinylcholine)
• Non-depolarising blockers (e.g. rocuronium, cisatracurium)
• Indications: intubation, severe dyssynchrony, early severe ARDS
• Mandatory concurrent sedation and analgesia
• Train-of-four monitoring of blockade depth
• ICU-acquired weakness as a potential harm

Mechanisms

Neuromuscular blockers interrupt signalling at the neuromuscular junction, where acetylcholine normally binds postsynaptic receptors to trigger muscle contraction. Non-depolarising agents competitively block the acetylcholine receptor, preventing depolarisation; depolarising agents such as succinylcholine first activate then desensitise the receptor, causing transient fasciculation followed by paralysis. Because these drugs abolish movement but have no sedative or analgesic effect, a paralysed patient who is inadequately sedated can be awake and in pain without being able to signal it — the rationale for always pairing blockade with sufficient sedation and analgesia. Depth of blockade can be monitored with peripheral nerve stimulation (train-of-four).

Clinical relevance

NMBAs enable specific critical-care interventions but carry distinct risks (awareness if under-sedated, and ICU-acquired weakness), so understanding their mechanism and the bounded indications for their use is important in critical care. This entry summarises the evidence and safety principles for orientation; it is not a protocol for administering paralytics.

Evidence & guidelines

In early severe ARDS, the ACURASYS trial (Papazian et al., 2010) reported improved outcomes with a short course of cisatracurium, but the later, larger ROSE trial (PETAL Network, 2019), conducted with a lighter-sedation comparator, found no mortality benefit — so current guidance reserves continuous neuromuscular blockade for selected situations. The 2018 PADIS guidelines (Devlin et al.) frame blockade within an analgesia- and sedation-first approach.

History

Curare-derived agents introduced controlled paralysis into anaesthesia in the mid-twentieth century. In critical care, enthusiasm for routine paralysis in respiratory failure was tempered by concerns about awareness and ICU-acquired weakness; the ACURASYS (2010) and ROSE (2019) trials then defined and narrowed the evidence-based role of early neuromuscular blockade in ARDS.

Debates

Does early neuromuscular blockade improve survival in severe ARDS?

ACURASYS suggested a benefit from early cisatracurium, but the larger ROSE trial — using a light-sedation control arm — found no mortality difference, so the value of routine early blockade in ARDS remains contested and context-dependent.

Key figures

• Laurent Papazian
• John Devlin

Seminal works

• papazian-2010
• petal-rose-2019

Frequently asked questions

Why must a paralysed patient also be sedated?

Neuromuscular blockers stop movement but produce no sedation or pain relief, so without adequate sedation and analgesia a paralysed patient could be awake and in pain yet unable to communicate.

Are neuromuscular blockers used routinely in the ICU?

No; they are reserved for specific indications such as facilitating intubation, controlling severe ventilator dyssynchrony, or selected cases of early severe ARDS, because of risks including awareness and ICU-acquired weakness.